Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.

By Raymond Schiffelers, A. Ansari, Jun Xu, Qin Zhou, Qingquan Tang, G. Storm, G. Molema, Patrick Y. Lu, P. Scaria, M. Woodle. Nucleic Acids Research, 2004

895 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/479064422d8015574df592eb5ede2e8b36e5d77e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. R. Juliano
2. P. Couvreur

In Molecular Biology

1. M. Manoharan
2. R. Juliano
3. I. Rubinstein
4. O. Koo
5. P. Couvreur
6. H. Onyuksel
7. M. Amiji
8. H. Hillaireau

Citations in the corpus

• The delivery of therapeutic oligonucleotides (2016, methodology): “For example, a branched PEI modified with PEG and Arg-GlyAsp (RGD) ligands was used to deliver siRNA to tumors in mice (218).”
• Delivery of siRNA Therapeutics: Barriers and Carriers (2010, background): “The resulting nanoparticles, upon intravenous administration to tumor-bearing mice, successfully delivered siRNA in a tumor-selective manner, inhibited vascular endothelial growth factor (VEGF) receptor-2 expression, inhibited tumor angiogenesis, and slowed tumor growth ( 59 ).”
• Nanocarriers’ entry into the cell: relevance to drug delivery (2009, background): “This can be explained by the predominance of other factors like the nature, the size and the surface charge of the nanodevices; multiple endocytic pathways can also be involved simultaneously (CME, CvME, RME, macropinocytosis).”
• Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery (2007, methodology): “PEG-PEI-siRNA nanoparticles Tumor tissue selective delivery Protein expression within tumor and tumor regression [ 43 ]”
• Antibody targeted drugs as cancer therapeutics (2006, background): “Ways to deliver siRNA to tumour cells include ligand-targeted nanoparticle”
• Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, background): “Vasoactive intestinal peptides Vasoactive intestinal peptide receptor Phospholipid micelles, liposomes [47,94,111] RGD peptide Cellular adhesion molecules such as integrins Polymer nanoparticles [45,46]”
• RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, background): “Intravenous administration of these complexes into tumor-bearing mice inhibits both tumor angiogenesis and growth rat”
• A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. (2011, background): “The arginine– glycine–aspartic acid (RGD) motif has frequently been used for the targeted delivery of drugs and genes because of its ability to recognise integrins that are expressed on both tumour cells and neovascular endothelial cells [52,53].”